Clinical Trial

Large Cohort of 1000 Patients With Severe Myopia

Study acronym: MyoCo1000
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The prevalence of myopia and severe myopia are increasing and will affect 50% and 10% of the population respectively. Severe myopia exposes an increased risk of glaucoma, cataract, retinal detachment and myopic maculopathy, a source of visual impairment. To date, no European cohort study has been conducted to estimate the rate of these complications and to study the predictive parameters.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-28.
Trial Details
NCT Number NCT05849974
Lead Sponsor Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Collaborators: Fondation Ophtalmologique Adolphe de Rothschild
Conditions Myopia, Severe
Enrollment 1,000 participants
Start Date 2023-06
Primary Completion 2038-05 (estimated)
Study Completion 2038-05 (estimated)
Updated on ClinicalTrials.gov 2023-05-23